
vTv Therapeutics (VTVT) Stock Forecast & Price Target
vTv Therapeutics (VTVT) Analyst Ratings
Bulls say
vTv Therapeutics is a well-positioned company with a promising drug candidate in development, a strong cash balance, and potential partnerships and expansion opportunities. While there are risks involved in the clinical trials and market competition, the positive results seen in trials and the potential for future partnerships make vTv a favorable investment option for those with a long-term outlook.
Bears say
vTv Therapeutics is a late-stage biopharmaceutical company that focuses on developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Despite the positive outlook for the FDA's prioritization of T1D and the potential for disease-modifying therapies, we have a negative outlook due to potential challenges in broad adoption of vTv's lead candidate cadisegliatin. Although it has shown promising results in reducing hypoglycemia and HbA1c, challenges such as regulatory hurdles, real-world adoption dynamics, and competition in the market may hinder its success. Additionally, our financial analysis indicates a potential peak revenue of $919M and a 12-month price target of $58, assuming a 60% probability of success.
This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
vTv Therapeutics (VTVT) Analyst Forecast & Price Prediction
Start investing in vTv Therapeutics (VTVT)
Order type
Buy in
Order amount
Est. shares
0 shares